Loading
A phase 2 trial of cisplatin, nab-paclitaxel, capecitabine and gemcitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer is a phase 2, interventional study registered as NCT07828756 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 147 participants, started 2026-09-30 and due to reach its primary completion in 2027-10-31. Interventions recorded: Cisplatin; Albumin-bound Paclitaxel (II); Albumin-bound Paclitaxel (II); Capecitabine; Capecitabine; Gemcitabine; Gemcitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival (PFS); 1-Year Event-Free Survival Rate (1y-EFS Rate); Recommended Phase 2 Dose (RP2D). Pancreatic eligibility wording from the registry: "* Histopathologically confirmed pancreatic adenocarcinoma meeting any one of the following conditions: (1) Unresectable locally advanced or metastatic pancreatic cancer, with no prior systemic anti-tumor therapy for advanced disease". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Capecitabine, Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.